Indian pharma rebranding, rare-disease treatment and infusion care.
Indian pharma industry
Novartis India renamed Evonile Pharma Limited
Novartis India Limited has changed its name to Evonile Pharma Limited, effective 1 October 2026, following Ministry of Corporate Affairs approval. Shareholders approved the change on 24 September. The listed company became part of the ChrysCapital group on 29 July 2026; Novartis continues its other operations in India.
Why it matters: The ownership and corporate identity transition is relevant to pharmaceutical professionals and business partners.
Oral achondroplasia treatment receives FDA Priority Review
BridgeBio announced FDA acceptance and Priority Review of its application for oral infigratinib for children with achondroplasia, with a target decision date of 4 February 2027. The submission includes Phase 3 growth data. The medicine remains investigational for this indication; Priority Review does not mean approval.
Why it matters: If approved, an oral option could expand treatment choices for children with achondroplasia.
McKesson and CD&R agree $5.8 billion Option Care acquisition
McKesson and Clayton Dubilier & Rice agreed to acquire infusion provider Option Care Health in a transaction valued at approximately $5.8 billion, including debt. McKesson plans to invest about $1.4 billion for a 49% stake. Completion is expected in the first half of 2027.
Why it matters: The deal highlights investment in home and ambulatory infusion services, relevant to specialty medicines and pharmaceutical distribution.
Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.